Denikitug

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameDenikitug
Drug Alias NameJTX-1811GS-1811
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionRegulatory T-lymphocytes inhibitorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsC-C chemokine receptor type 8 inhibitors
TargetsC-C chemokine receptor type 8
Therapy Area/IndicationsEsophageal adenocarcinomaSolid tumoursStomach Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaIND
Originator CompaniesJounce Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesGilead Sciences Inc
Inactive CompaniesN/A
Active IndicationsEsophageal adenocarcinomaSolid tumoursStomach Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A